- Home
- MTEK vs RVPH Comparison
MTEK vs RVPH Comparison
Compare MTEK & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEK
- RVPH
- Stock Information
- Founded
- MTEK 2008
- RVPH 2006
- Country
- MTEK Israel
- RVPH United States
- Employees
- MTEK N/A
- RVPH N/A
- Industry
- MTEK
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- MTEK
- RVPH Health Care
- Exchange
- MTEK Nasdaq
- RVPH Nasdaq
- Market Cap
- MTEK 26.9M
- RVPH 26.6M
- IPO Year
- MTEK 2022
- RVPH N/A
- Fundamental
- Price
- MTEK $3.21
- RVPH $0.49
- Analyst Decision
- MTEK
- RVPH Strong Buy
- Analyst Count
- MTEK 0
- RVPH 5
- Target Price
- MTEK N/A
- RVPH $9.00
- AVG Volume (30 Days)
- MTEK 51.2K
- RVPH 3.2M
- Earning Date
- MTEK 08-27-2025
- RVPH 08-13-2025
- Dividend Yield
- MTEK N/A
- RVPH N/A
- EPS Growth
- MTEK N/A
- RVPH N/A
- EPS
- MTEK N/A
- RVPH N/A
- Revenue
- MTEK $6,078,953.00
- RVPH N/A
- Revenue This Year
- MTEK N/A
- RVPH N/A
- Revenue Next Year
- MTEK N/A
- RVPH N/A
- P/E Ratio
- MTEK N/A
- RVPH N/A
- Revenue Growth
- MTEK 50.80
- RVPH N/A
- 52 Week Low
- MTEK $1.54
- RVPH $0.30
- 52 Week High
- MTEK $6.47
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- MTEK 51.25
- RVPH 50.12
- Support Level
- MTEK $3.30
- RVPH $0.38
- Resistance Level
- MTEK $3.49
- RVPH $0.45
- Average True Range (ATR)
- MTEK 0.22
- RVPH 0.04
- MACD
- MTEK -0.04
- RVPH 0.03
- Stochastic Oscillator
- MTEK 15.56
- RVPH 72.37
About MTEK Maris-Tech Ltd.
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.